BACKGROUND: The prevalence of airflow limitation (AL) in patients with cardiovascular disease (CVD) is unknown, and whether AL is adequately diagnosed and treated in these patients has not been investigated before, to our knowledge. METHODS: We compared clinical and spirometric data in three groups of individuals. Two of them were participants in the follow-up of an ongoing population-based study according to the presence or absence of CVD. The third group included patients with coronary artery disease (CAD) confirmed by coronariography regularly visited at a tertiary referral university hospital. AL was defined according to the Global Initiative for Obstructive Lung Disease guidelines. RESULTS: We studied 450 population participants without CVD, 52 population participants with CVD, and 119 hospital patients with CAD. The prevalence of AL in these three groups was 17.5% (95% CI, 14.0-21.0), 19.2% (95% CI, 8.1-30.7), and 33.6% (95% CI, 25.0-42.2), respectively (P < .05). Underdiagnosis of AL ranged from 60% in population participants with CVD up to 87.2% in hospital patients with CAD. Sixty percent of those with spirometrically confirmed AL (in all three groups) did not receive any respiratory treatment. CONCLUSIONS: AL is frequent in individuals with CVD, particularly in those with CAD attended in the hospital, is largely underdiagnosed and therefore is highly undertreated. TRIAL REGISTRATION: Clinicaltrials.gov; Identifier: NCT00787748.
BACKGROUND: The prevalence of airflow limitation (AL) in patients with cardiovascular disease (CVD) is unknown, and whether AL is adequately diagnosed and treated in these patients has not been investigated before, to our knowledge. METHODS: We compared clinical and spirometric data in three groups of individuals. Two of them were participants in the follow-up of an ongoing population-based study according to the presence or absence of CVD. The third group included patients with coronary artery disease (CAD) confirmed by coronariography regularly visited at a tertiary referral university hospital. AL was defined according to the Global Initiative for Obstructive Lung Disease guidelines. RESULTS: We studied 450 population participants without CVD, 52 population participants with CVD, and 119 hospital patients with CAD. The prevalence of AL in these three groups was 17.5% (95% CI, 14.0-21.0), 19.2% (95% CI, 8.1-30.7), and 33.6% (95% CI, 25.0-42.2), respectively (P < .05). Underdiagnosis of AL ranged from 60% in population participants with CVD up to 87.2% in hospital patients with CAD. Sixty percent of those with spirometrically confirmed AL (in all three groups) did not receive any respiratory treatment. CONCLUSIONS:AL is frequent in individuals with CVD, particularly in those with CAD attended in the hospital, is largely underdiagnosed and therefore is highly undertreated. TRIAL REGISTRATION: Clinicaltrials.gov; Identifier: NCT00787748.
Authors: Komal Malik; Susana Diaz-Coto; Maria de la Asunción Villaverde; Pablo Martinez-Camblor; Annie Navarro-Rolon; Francisco Pujalte; Alejandro De la Sierra; Pere Almagro Journal: Int J Chron Obstruct Pulmon Dis Date: 2022-10-14
Authors: Tomas Konecny; Kiran R Somers; Jae Yoon Park; Alan John; Marek Orban; Rahul Doshi; Paul D Scanlon; Samuel J Asirvatham; Charanjit S Rihal; Peter A Brady Journal: Heart Rhythm Date: 2017-10-03 Impact factor: 6.343
Authors: José Luis Izquierdo; Arturo Martínez; Elizabet Guzmán; Pilar de Lucas; José Miguel Rodríguez Journal: Int J Chron Obstruct Pulmon Dis Date: 2010-11-08
Authors: Pere Almagro; Anna Lapuente; Julia Pareja; Sergi Yun; Maria Estela Garcia; Ferrán Padilla; Josep L I Heredia; Alex De la Sierra; Joan B Soriano Journal: Int J Chron Obstruct Pulmon Dis Date: 2015-07-16